Clinical trials: Prostate Cancer Recurrent
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT03279250
- Testing
- Abiraterone Acetate, Apalutamide, Gonadotropin-releasing Hormone Analog
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Genistein in Treating Patients With Prostate Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT01126879
- Testing
- genistein, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Metastatic Cancer, Pain
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
RATIONALE: Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well tandutinib works in treating patients with progressive prostate…
- Conditions
- Metastatic Cancer, Pain, Prostate Cancer
- Trial name
- NCT00390468
- Testing
- Tandutinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00049257
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of alisertib when given together with abiraterone acetate and prednisone and to see how well it works in treating patients with hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01848067
- Testing
- Alisertib, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02985021
- Testing
- Carboplatin, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate…
- Trial name
- SABRE (NCT05407311)
- Testing
- 64Cu-SAR-BBN
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
The aim of this study is to test whether adding chemotherapy/cabazitaxel and hormonal/androgen deprivation therapy before surgical removal of your prostate would improve the outcome of salvage surgery for locally recurrent…
- Trial name
- NCT01531205
- Testing
- Androgen Ablation, Cabazitaxel, Salvage Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Lung Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with…
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00365105
- Testing
- Calcium, Vitamin D, zoledronic acid
- Where
- 147 sites in United States
- Volunteers
- 261 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01051570
- Testing
- carboplatin, RAD 001, prednisone
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Cancer, Prostate Cancer
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00134056
- Testing
- atrasentan hydrochloride, docetaxel, prednisone
- Where
- 554 sites in United States
- Volunteers
- 1,038 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with…
- Trial name
- NCT01054079
- Testing
- laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Prostate Cancer
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
This phase II trial studies how well fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging (MRI) work in finding metastases in patients with…
- Trial name
- NCT01967862
- Testing
- computed tomography, bone scan, 3-Tesla magnetic resonance imaging
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Recurrent Prostate Cancer
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
It is estimated that one-third of the more than 7 million deaths from cancer worldwide are attributable to potentially modifiable risk factors, with 374,000 deaths preventable through diet modification alone.
- Trial name
- NCT03496805
- Testing
- MGE, ADT
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
The purpose of this study is to describe the 2 year progression-free survival in men with recurrent PSA-only disease after prostatectomy receiving combined enzalutamide and standard androgen-deprivation therapy (ADT) with salvage…
- Trial name
- STREAM (NCT02057939)
- Testing
- enzalutamide, Androgen Deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Prostate Cancer
Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the…
- Trial name
- BAT (NCT01750398)
- Testing
- Testosterone cypionate, Goserelin, Leuprolide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Saracatinib in Treating Patients With Prostate Cancer
This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01267266
- Testing
- saracatinib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with cyclophosphamide and to see how well they work in treating patients with previously treated hormone-refractory prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01093183
- Testing
- lenalidomide, cyclophosphamide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Nebraska
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer